Dr. Anderson is a professor and serves as the director of the Myeloma, Waldenstrom’s, and Amyloidosis Program at UT Southwestern Medical Center in Dallas, a program that he developed since joining UT Southwestern in 2008. He is also the director of the Hematologic Malignancies and Cellular Therapy Clinical Research Program, Co-Director of the Phase 1 Clinical Trial Research Program, and Co-Director of the Cellular Immunotherapy and Autologous Stem Cell Transplant Program. He specializes in the treatment of plasma cell disorders including multiple myeloma, Waldenstrom’s macroglobulinemia, and amyloidosis. He has a particular interest in cellular therapies including CAR T-cells and stem cell transplantation, but he takes care of plasma cell disorder patients from diagnosis through maintenance and relapse therapy or clinical trials. He has over 17 years of experience with plasma cell disorders and stem cell transplantation after completion of his medical oncology fellowship at Fred Hutchinson Cancer Research Center and University of Washington in Seattle. He did his residency in internal medicine at Mayo Clinic Rochester and his MD and PhD degrees were received from UT Health Science Center at Houston and MD Anderson Cancer Center. He runs an active clinical trial program for the spectrum of plasma cell disorders with a focus on immunotherapies and CAR T-cell therapy and has been a lead enroller in several key myeloma trials, which has helped his program become a world class center of excellence for plasma cell disorders.